Department of Haematological Medicine, King's College London, London, UK.
Leuk Res. 2010 Jul;34(7):837-42. doi: 10.1016/j.leukres.2010.03.011. Epub 2010 Mar 31.
Bcl-2 family proteins have long been implicated in the pathology of chronic lymphocytic leukaemia (CLL). Indeed, a number of these proteins have been shown to have prognostic importance in this disease. The precise ways in which these proteins impact upon CLL and the ways in which they are regulated remain incompletely resolved. However, significant advances have been recently made in our understanding of how these proteins are controlled by genetic, epigenetic and microenvironmental cues. Furthermore, major progress has been made in trying to target these proteins therapeutically. Here we review the current knowledge about this family of apoptosis-regulating proteins and how they impact upon drug resistance and disease progression. We also summarise evolution in the development of Bcl-2 family inhibitors for the treatment of CLL and other cancers.
Bcl-2 家族蛋白一直与慢性淋巴细胞白血病（CLL）的病理学有关。事实上，这些蛋白中的许多已被证明在该疾病中具有预后意义。这些蛋白对 CLL 的影响以及它们的调节方式仍不完全清楚。然而，最近在我们对这些蛋白如何受到遗传、表观遗传和微环境线索控制的理解方面取得了重大进展。此外，在尝试将这些蛋白作为治疗靶点方面也取得了重大进展。在这里，我们回顾了有关该凋亡调节蛋白家族的现有知识，以及它们如何影响耐药性和疾病进展。我们还总结了 Bcl-2 家族抑制剂治疗 CLL 和其他癌症的开发进展。
